Boston Scientific Corporation (NYSE:BSX) issued an update on its fourth quarter earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.32-0.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.34. The company issued revenue guidance of $2.345-2.375, compared to the consensus revenue estimate of $2.32 billion.
Shares of Boston Scientific Corporation (NYSE BSX) opened at $28.36 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93. The firm has a market capitalization of $38,943.84, a price-to-earnings ratio of 23.25, a P/E/G ratio of 2.19 and a beta of 1.00.
Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.31. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.27 earnings per share. equities analysts forecast that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on BSX shares. UBS AG restated a buy rating and issued a $31.00 price objective (up from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. BidaskClub cut Boston Scientific Corporation from a buy rating to a hold rating in a research report on Tuesday, July 25th. SunTrust Banks, Inc. set a $34.00 price target on Boston Scientific Corporation and gave the company a buy rating in a research report on Tuesday, October 31st. Zacks Investment Research cut Boston Scientific Corporation from a buy rating to a hold rating in a research report on Monday, October 30th. Finally, Oppenheimer Holdings, Inc. restated a hold rating on shares of Boston Scientific Corporation in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $30.77.
In other Boston Scientific Corporation news, EVP Supratim Bose sold 347,137 shares of the company’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $29.12, for a total transaction of $10,108,629.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Maulik Nanavaty sold 57,031 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $27.28, for a total value of $1,555,805.68. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock worth $14,581,669 in the last quarter. Company insiders own 0.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/boston-scientific-corporation-bsx-releases-q4-earnings-guidance.html.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.